Compare FWRD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | ARVN |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 600.2M |
| IPO Year | 2024 | 2018 |
| Metric | FWRD | ARVN |
|---|---|---|
| Price | $15.09 | $7.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $24.50 | $13.93 |
| AVG Volume (30 Days) | 391.2K | ★ 657.0K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | ★ $1,269,573,000.00 | $262,600,000.00 |
| Revenue This Year | $3.56 | $12.76 |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | ★ N/A | $4.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.86 | $6.74 |
| 52 Week High | $31.18 | $14.22 |
| Indicator | FWRD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 38.65 |
| Support Level | $14.84 | N/A |
| Resistance Level | $16.76 | $7.74 |
| Average True Range (ATR) | 0.73 | 0.33 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 16.41 | 30.74 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.